The need to know biotech news stories today
A new study shows that people vaccinated against Ebola with a single dose of Merck’s Ervebo are far less likely to die than those who aren’t vaccinated, even if they do…
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Hi! It’s Meghana. Today, some amazing intel on Merck’s Ebola vaccine: Turns out, it can reduce risk of death, even after a person has been infected. Also, investors bet on another obesity drug — this time from BioAge, which is combining Zepbound with a pill that keeps muscle wasting at bay.
What's Your Reaction?
